Lormetazepam

Lormetazepam is a short-acting benzodiazepine with general properties similar to those of diazepam. Lormetazepam is used as a hypnotic in the short-term management of insomnia.

Lormetazepam is primarily indicated in conditions like Insomnia, Nausea, vertigo, labyrinthine disorders.

Lormetazepam is contraindicated in conditions like Myasthenia gravis, Respiratory depression, Acute pulmonary insufficiency, Sleep apnea syndrome.

The symptomatic adverse reactions produced by Lormetazepam are more or less tolerable and if they become severe, they can be treated symptomatically, these include Sleepiness, Headache, Ataxia.

Lormetazepam should be used with caution in patients with respiratory disease, muscle weakness, history of drug or alcohol abuse, marked personality disorder; avoid regular use during pregnancy (risk of neonatal withdrawal symptoms); use only if clear indication such as seizure control (high doses during late pregnancy or labor may cause neonatal hypothermia, hypotonia and respiratory depression), breast-feeding (present in milk, avoid if possible); reduce dose in elderly and debilitated, and in hepatic (avoid if severe) and renal impairment (start with small doses if severe); avoid prolong use (abrupt withdrawal thereafter); porphyria. It should not be used alone to treat depression (or anxiety associated with depression) or psychosis

If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

0.5 to 1.5 mg (1 (1)) 24 hourly PO — Once at bed time

( ) — Not recommended in this age group

No neonatal dosage information is recorded for this medicine yet.

No data regarding the interactions of Lormetazepam was found.

Tab Store . Protect from Sunlight.